AbbVie has completed the acquisition of ImmunoGen for $10.1bn, a move that significantly bolsters its oncology pipeline with promising treatments for solid tumours and haematologic malignancies.

However, over the past decade, companies including Seattle Genetics and ImmunoGen have extensively researched the ideal characteristics of an ADC. “It took a while to figure out that you need to ...

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

The research team, led by Dr. Mihai Azoitei, associate professor at the Duke Human Vaccine Institute and the Department of Cell Biology, has created an immunogen -- a substance that provokes an ...

The U.S. Patent and Trademark Office has a history of attempting to challenge judicial decisions that the Office, usually for its own policy ...

The resulting immunogen activated diverse precursors of an HIV V3-glycan bnAb—antibodies that target a key site of vulnerability on the outer envelope of the virus—and promote their ...

PopVax’s prize-winning vaccine is built on its mRNA-encoded immunogen display approach, machine learning-enabled immunogen design feedback loop, and lipid nanoparticle (LNP) platform that boost ...